Physician profile
Consolate Oburu Bindom
NPI 1326478835
$3,253.08
in general payments reported to CMS, 2019-2025
12 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $651 · 2023: $615 · 2024: $701 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,477.94 | 2021-2024 | Xarelto, Abiraterone Acetate |
| Abbvie INC. | $326.82 | 2022-2024 | |
| Lilly USA, LLC | $275.49 | 2022-2025 | Zepbound |
| Axsome Therapeutics, INC. | $195.26 | 2025 | Auvelity |
| Abbott Laboratories | $134.84 | 2021 | |
| Medtronic, INC. | $132.12 | 2024 | Cobalt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Genzyme Corporation | $122.92 | 2021 | |
| Amgen INC. | $122.86 | 2021 | |
| Glaxosmithkline, LLC. | $122.09 | 2024 | Arexvy |
| Astrazeneca Pharmaceuticals Lp | $115.34 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $102.40 | 2024 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Consolate Oburu Bindom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.